288 related articles for article (PubMed ID: 27655686)
41. Inhibition of mitochondrial respiration and rapid depletion of mitochondrial glutathione by β-phenethyl isothiocyanate: mechanisms for anti-leukemia activity.
Chen G; Chen Z; Hu Y; Huang P
Antioxid Redox Signal; 2011 Dec; 15(12):2911-21. PubMed ID: 21827296
[TBL] [Abstract][Full Text] [Related]
42. Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of caspase-3, mitochondria dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2 OS cells.
Wu CL; Huang AC; Yang JS; Liao CL; Lu HF; Chou ST; Ma CY; Hsia TC; Ko YC; Chung JG
J Orthop Res; 2011 Aug; 29(8):1199-209. PubMed ID: 21374707
[TBL] [Abstract][Full Text] [Related]
43. Elevated
Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
45. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
46. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
47. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.
Li Q; Zhan M; Chen W; Zhao B; Yang K; Yang J; Yi J; Huang Q; Mohan M; Hou Z; Wang J
Oncotarget; 2016 Mar; 7(9):10271-82. PubMed ID: 26848531
[TBL] [Abstract][Full Text] [Related]
48. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
49. Phenethyl isothiocyanate inhibits growth of human chronic myeloid leukemia K562 cells via reactive oxygen species generation and caspases.
Wang Y; Wei S; Wang J; Fang Q; Chai Q
Mol Med Rep; 2014 Jul; 10(1):543-9. PubMed ID: 24788892
[TBL] [Abstract][Full Text] [Related]
50. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
51. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
Lucas DM; Edwards RB; Lozanski G; West DA; Shin JD; Vargo MA; Davis ME; Rozewski DM; Johnson AJ; Su BN; Goettl VM; Heerema NA; Lin TS; Lehman A; Zhang X; Jarjoura D; Newman DJ; Byrd JC; Kinghorn AD; Grever MR
Blood; 2009 May; 113(19):4656-66. PubMed ID: 19190247
[TBL] [Abstract][Full Text] [Related]
52. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
53. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
54. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
[TBL] [Abstract][Full Text] [Related]
55. The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.
Agnoletto C; Brunelli L; Melloni E; Pastorelli R; Casciano F; Rimondi E; Rigolin GM; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2015 Feb; 6(4):2385-96. PubMed ID: 25544776
[TBL] [Abstract][Full Text] [Related]
56. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
57. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
Cramer SL; Saha A; Liu J; Tadi S; Tiziani S; Yan W; Triplett K; Lamb C; Alters SE; Rowlinson S; Zhang YJ; Keating MJ; Huang P; DiGiovanni J; Georgiou G; Stone E
Nat Med; 2017 Jan; 23(1):120-127. PubMed ID: 27869804
[TBL] [Abstract][Full Text] [Related]
58. Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo.
Lam-Ubol A; Fitzgerald AL; Ritdej A; Phonyiam T; Zhang H; Myers JN; Huang P; Trachootham D
Food Funct; 2018 Jul; 9(7):3640-3656. PubMed ID: 29923573
[TBL] [Abstract][Full Text] [Related]
59. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
Messmer BT; Nour-Omid TS; Ghia E; Sanchez AB; Kipps TJ
Leuk Res; 2011 Jul; 35(7):965-7. PubMed ID: 21570119
[TBL] [Abstract][Full Text] [Related]
60. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
Lin K; Lane B; Carter A; Johnson GG; Onwuazor O; Oates M; Zenz T; Stilgenbauer S; Atherton M; Douglas A; Ebrahimi B; Sherrington PD; Pettitt AR
Br J Haematol; 2013 Jan; 160(1):53-62. PubMed ID: 23110309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
